Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) Research & Development (2020 - 2025)

INVO Fertility (IVF) has disclosed Research & Development for 7 consecutive years, with $127807.0 as the latest value for Q2 2025.

  • On a quarterly basis, Research & Development changed N/A to $127807.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $878250.0, a 8041.74% increase, with the full-year FY2024 number at $489660.0, up 195.07% from a year prior.
  • Research & Development was $127807.0 for Q2 2025 at INVO Fertility, down from $265663.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $484780.0 in Q4 2024 to a low of $2668.0 in Q3 2023.
  • A 5-year average of $113096.8 and a median of $73677.5 in 2022 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: tumbled 98.48% in 2023, then skyrocketed 8106.87% in 2024.
  • INVO Fertility's Research & Development stood at $63756.0 in 2021, then increased by 15.81% to $73835.0 in 2022, then plummeted by 92.0% to $5907.0 in 2023, then surged by 8106.87% to $484780.0 in 2024, then tumbled by 73.64% to $127807.0 in 2025.
  • Per Business Quant, the three most recent readings for IVF's Research & Development are $127807.0 (Q2 2025), $265663.0 (Q1 2025), and $484780.0 (Q4 2024).